A new peer-reviewed article on TK 210 ELISA was released today
An article has been published in the PLOS One journal, where the study demonstrates the robustness and simplicity of the AroCell TK 210 ELISA assay compared to TK activity assays.
The article entitled “Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples”, by Kiran Jagarlamudi et al., briefly describes the antibody selection and different phases in AroCell TK 210 ELISA assay development and assess in detail the analytical performance of the TK 210 ELISA to demonstrate the robustness and simplicity of the assay compared to TK activity assays.
The evaluation of the clinical performance showed that the AroCell TK 210 ELISA has a higher sensitivity for TK1 in serum from subjects with solid tumors and a similar sensitivity as TK1 activity for hematological malignancies. This suggests that the AroCell TK 210 ELISA facilitate the application of TK1 as a biomarker for solid tumors and also broadens the clinical applications of TK1 in cancer management.
The article can be read here:
https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0275444